logo
Plus   Neg
Share
Email

High Arctic Energy Gets Necessary Approvals To Conduct Normal Course Issuer Bid

High Arctic Energy Services Inc. (HWO.TO) said it has made the necessary filings, and received the necessary approvals to conduct a normal course issuer bid through the facilities of the Toronto Stock Exchange.

The TSX has accepted the Corporation's notice to conduct the normal course issuer bid to purchase outstanding common shares on the open market, in accordance with the rules of the TSX. As approved by the TSX, the Corporation is authorized to purchase up to 2.48 million common shares, representing approximately 5% of the currently issued and outstanding common shares of the Corporation.

As of today's date, there are 49.62 million common shares outstanding. On any trading day, High Arctic will not purchase more than 6,248 common shares, other than through block purchase exceptions.

The Corporation is authorized to make purchases during the period from March 23, 2012 to March 22, 2013, or until such earlier time as the normal course issuer bid is completed or terminated at the option of the Corporation.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT